Use of neural networks for dosage individualisation of erythropoietin in patients with secondary anemia to chronic renal failure.
The external administration of recombinant human erythropoietin is the chosen treatment for those patients with secondary anemia due to chronic renal failure undergoing periodic hemodialysis. The goal is to carry out an individualised prediction of the erythropoietin dosage to be administered. It is justified because of the high cost of this medication, its secondary effects and the phenomenon of potential resistance which some individuals suffer. One hundred and ten patients were included in this study and several factors were collected in order to develop the neural models. Since the results obtained were excellent, an easy-to-use decision-aid computer application was implemented.
Martín Guerrero
José D
JD
Digital Signal Processing Group, Department of Electronics Engineering, Faculty of Physics, University of València, C del Dr. Moliner 50, Burjassot 46100, València, Spain. jose.d.martin@uv.es
Olivas
Emilio Soria
ES
Valls
Gustavo Camps
GC
Serrano López
Antonio J
AJ
Pérez Ruixo
Juan J
JJ
Torres
N Víctor Jiménez
NV
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000503:physiopathology; D016571:Neural Networks, Computer; D011788:Quality of Life; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin